CVT 510

Known as: CVT-510 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Termination of Paroxysmal Supraventricular Tachycardia by Tecadenoson (CVT-510), a Novel A1-Adenosine Receptor Agonist Eric N… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2010
2010
Publication of this article is suspended until the authors can provide full identification and verification of the chemical… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Selective pharmacological activation of the adenosine 1 receptor (A(1)R) is a promising new approach to achieve a potent block of… (More)
Is this relevant?
Review
2003
Review
2003
Adenosine is an endogenous nucleoside that has potent antiarrhythmic effects on paroxysmal supraventricular tachycardia (PSVT… (More)
Is this relevant?
2003
2003
OBJECTIVES The aim of this study was to evaluate tecadenoson safety and efficacy during conversion of paroxysmal supraventricular… (More)
Is this relevant?
2003
2003
Elevated serum nonesterified free fatty acid (NEFA) concentrations are detrimental to both the mechanical and electrical function… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 5
  • figure 4
Is this relevant?
Review
2002
Review
2002
CVT-510, the lead compound from a series of selective adenosine A1 receptor agonists, is being developed by CV Therapeutics for… (More)
Is this relevant?
2001
2001
BACKGROUND CVT-510, N-(3(R)-tetrahydrofuranyl)-6-aminopurine riboside, is a selective A(1)-adenosine receptor agonist with… (More)
Is this relevant?